Kanjinti

Trastuzumab, the active ingredient in Kanjinti, is a monoclonal antibody presented as a 40 mg/mL injection solution for intravenous use. It treats HER2‑positive breast cancer and HER2‑positive gastric/gastro‑esophageal adenocarcinoma in adult patients.

GNH USA supplies Kanjinti as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

Kanjinti (trastuzumab) is indicated for HER2‑positive cancers, targeting the HER2 receptor pathway.

- HER2‑positive metastatic breast cancer: improves overall survival and disease control in adult patients. - HER2‑positive early breast cancer (adjuvant setting): reduces risk of recurrence after surgery. - HER2‑positive gastric/gastro‑esophageal adenocarcinoma: used in combination therapy to improve response rates.

Kanjinti may be associated with a range of adverse reactions observed in clinical use.

Common Side Effects: - Fever: transient elevation of body temperature. - Nausea: mild to moderate gastrointestinal upset. - Fatigue: general tiredness or lack of energy. - Infusion‑related reactions: chills, flushing, or shortness of breath during administration.

Serious or Rare Side Effects: - Cardiac dysfunction: decreased left ventricular ejection fraction or heart failure. - Severe infusion reactions: anaphylaxis or bronchospasm. - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Hepatotoxicity: elevated liver enzymes or hepatitis.

When using Kanjinti, clinicians should observe several safety measures.

- Cardiac monitoring: assess baseline and periodic left ventricular function. - Infusion reactions: monitor patients during and after infusion for signs of hypersensitivity. - Pregnancy: avoid use; safety not established in pregnant women. - Breastfeeding: discontinue if nursing; trastuzumab may be present in milk. - Concomitant therapies: evaluate potential additive toxicities with cardiotoxic agents. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Kanjinti can interact with other medicines; awareness of the interaction level is important.

Major Interactions (Avoid): - Anthracyclines (e.g., doxorubicin): combined use increases risk of cardiac toxicity. - Other HER2‑targeted agents (e.g., pertuzumab) administered concurrently: may enhance cardiotoxic risk.

Moderate Interactions (Monitor Closely): - Paclitaxel or other taxanes: monitor for increased infusion reactions. - Vaccines: live vaccines should be avoided during treatment. - Overlapping toxicities: watch for additive effects when combined with other agents that affect cardiac or hepatic function.